DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients

DNA Repair

Volumn 11, Issue 4, 2012, Pages 374-380

  Schena, Marina ^a   Guarrera, Simonetta ^b   Buffoni, Lucio ^a   Salvadori, Angelica ^a   Voglino, Floriana ^b   Allione, Alessandra ^b   Pecorari, Giancarlo ^a   Ruffini, Enrico ^a   Garzino Demo, Paolo ^a   Bustreo, Sara ^a   Consito, Lorena ^a   Bironzo, Paolo ^a   Matullo, Giuseppe ^b,c  

^a MOLINETTE HOSPITAL   (Italy)

^b Human Genetics Foundation   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

DNA repair; ERCC1; Gene expression; Head and neck cancer; Lung cancer

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP C PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; XRCC3 PROTEIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA REPAIR; FEMALE; GENE EXPRESSION; GENE TARGETING; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CANCER; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR GENE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA REPAIR; DNA REPAIR ENZYMES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL;

EID: 84858999704     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2012.01.003     Document Type: Article

References (53)

1. Benhamou S., Sarasin A. Variability in nucleotide excision repair and cancer risk: a review. Mutat. Res. 2000, 462:149-158.
2. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411:366-374.
3. Friedberg E.C. How nucleotide excision repair protects against cancer. Nat. Rev. Cancer 2001, 1:22-33.
4. Sugasawa K., Okamoto T., Shimizu Y., Masutani C., Iwai S., Hanaoka F. A multistep damage recognition mechanism for global genomic nucleotide excision repair. Genes Dev. 2001, 15:507-521.
5. Lindahl T., Karran P., Wood R.D. DNA excision repair pathways. Curr. Opin. Genet. Dev. 1997, 7:158-169.
6. Sancar A. DNA excision repair. Annu. Rev. Biochem. 1996, 65:43-81.
7. Kiyohara C., Otsu A., Shirakawa T., Fukuda S., Hopkin J.M. Genetic polymorphisms and lung cancer susceptibility: a review. Lung Cancer 2002, 37:241-256.
8. Ratnasinghe D., Yao S.X., Tangrea J.A., Qiao Y.L., Andersen M.R., Barrett M.J., Giffen C.A., Erozan Y., Tockman M.S., Taylor P.R. Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 2001, 10:119-123.
9. Divine K.K., Gilliland F.D., Crowell R.E., Stidley C.A., Bocklage T.J., Cook D.L., Belinsky S.A. The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. Mutat. Res. 2001, 461:273-278.
10. Qian B., Zhang H., Zhang L., Zhou X., Yu H., Chen K. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer 2011, 73(2):138-146.
11. Koç E., Caner V., Büyükpi{dotless}narbaşi{dotless}li{dotless} N., Tepeli E., Türk N.S., Ozan çetin G., Baĝci{dotless} G. The determination of relationship between "excision repair cross-complementing group 1" (ERCC1) gene T19007C and C8092A single nucleotide polymorphisms and clinicopathological parameters in non-small cell lung cancer. Mol. Biol. Rep. 2012, 39(1):375-380.
12. Shao M., Ma H., Wang Y., Xu L., Yuan J., Hu Z., Yang L., Wang F., Liu H., Qian J., Xun P., Chen W., Yuan W., Jing G., Chen F., Jin L., Wei Q., Wu T., Shen H., Huang W., Lu D. Polymorphisms in excision repair cross-complementing group 4 (ERCC4) and susceptibility to primary lung cancer in a Chinese Han population. Lung Cancer 2008, 60:332-339.
13. Matakidou A., el Galta R., Webb E.L., Rudd M.F., Bridle H., Eisen T., Houlston R.S. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum. Mol. Genet. 2007, 16:2333-2340.
14. Zienolddiny S., Campa D., Lind H., Ryberg D., Skaug V., Stangeland L., Phillips D.H., Canzian F., Haugen A. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 2006, 27:560-567.
15. Sturgis E.M., Castillo E.J., Li L., Zheng R., Eicher S.A., Clayman G.L., Strom S.S., Spitz M.R., Wei Q. Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis 1999, 20:2125-2129.
16. Sturgis E.M., Zheng R., Li L., Castillo E.J., Eicher S.A., Chen M., Strom S.S., Spitz M.R., Wei Q. XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. Carcinogenesis 2000, 21:2219-2223.
17. Li C., Hu Z., Lu J., Liu Z., Wang L.E., El-Naggar A.K., Sturgis E.M., Spitz M.R., Wei Q. Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck. Cancer 2007, 110:867-875.
18. Shen H., Sturgis E.M., Dahlstrom K.R., Zheng Y., Spitz M.R., Wei Q. A variant of the DNA repair gene XRCC3 and risk of squamous cell carcinoma of the head and neck: a case-control analysis. Int. J. Cancer 2002, 99:869-872.
19. Abbasi R., Ramroth H., Becher H., Dietz A., Schmezer P., Popanda O. Laryngeal cancer risk associated with smoking and alcohol consumption is modified by genetic polymorphisms in ERCC5, ERCC6 and RAD23B but not by polymorphisms in five other nucleotide excision repair genes. Int. J. Cancer 2009, 125:1431-1439.
20. Pan J., Lin J., Izzo J.G., Liu Y., Xing J., Huang M., Ajani J.A., Wu X. Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway. Carcinogenesis 2009, 30:785-792.
21. Tse D., Zhai R., Zhou W., Heist R.S., Asomaning K., Su L., Lynch T.J., Wain J.C., Christiani D.C., Liu G. Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk. Cancer Causes Control 2008, 19:1077-1083.
22. Liu G., Zhou W., Yeap B.Y., Su L., Wain J.C., Poneros J.M., Nishioka N.S., Lynch T.J., Christiani D.C. XRCC1 XPD polymorphisms and esophageal adenocarcinoma risk. Carcinogenesis 2007, 28:1254-1258.
23. Huang W.Y., Olshan A.F., Schwartz S.M., Berndt S.I., Chen C., Llaca V., Chanock S.J., Fraumeni J.F., Hayes R.B. Selected genetic polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and risk of head and neck cancer: a pooled analysis. Cancer Epidemiol. Biomarkers Prev. 2005, 14:1747-1753.
24. Wozniak K., Blasiak J. Recognition and repair of DNA-cisplatin adducts. Acta Biochim. Pol. 2002, 49:583-596.
25. Kartalou M., Essigmann J.M. Recognition of cisplatin adducts by cellular proteins. Mutat. Res. 2001, 478:1-21.
26. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., Cardenal F., Sanchez J.M., Gumerlock P.H., Taron M., Sanchez J.J., Danenberg K.D., Danenberg P.V., Rosell R. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 2002, 8:2286-2291.
27. Rosell R., Danenberg K.D., Alberola V., Bepler G., Sanchez J.J., Camps C., Provencio M., Isla D., Taron M., Diz P., Artal A. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 2004, 10:1318-1325.
28. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., Taranchon E., Filipits M., Pirker R., Popper H.H., Stahel R., Sabatier L., Pignon J.P., Tursz T., Le Chevalier T., Soria J.C. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006, 355:983-991.
29. Sun J.M., Ahn M.J., Park M.J., Lee H.Y., Ahn J.S., Lee S., Kang G., Han J., Son Y.I., Baek C.H., Ahn Y.C., Park K. Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2011, 80:655-660.
30. Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J.J., Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest. 1994, 94:703-708.
31. Reed E., Dabholkar M., Thornton K., Thompson C., Yu J.J., Bostick-Bruton F. Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues. Oncol. Rep. 2000, 7:1123-1128.
32. Selvakumaran M., Pisarcik D.A., Bao R., Yeung A.T., Hamilton T.C. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003, 63:1311-1316.
33. Britten R.A., Liu D., Tessier A., Hutchison M.J., Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int. J. Cancer 2000, 89:453-457.
34. Huang Z.H., Hua D., Du X., Li L.H., Mao Y., Liu Z.H., Song M.X., Zhou X.K. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J. Gastroenterol. 2008, 14:6401-6407.
35. Brabender J., Vallbohmer D., Grimminger P., Hoffmann A.C., Ling F., Lurje G., Bollschweiler E., Schneider P.M., Holscher A.H., Metzger R. ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus. J. Gastrointest. Surg. 2008, 12:1815-1821.
36. Zheng Z., Chen T., Li X., Haura E., Sharma A., Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med. 2007, 356:800-808.
37. Lee K.H., Min H.S., Han S.W., Oh D.Y., Lee S.H., Kim D.W., Im S.A., Chung D.H., Kim Y.T., Kim T.Y., Heo D.S., Bang Y.J., Sung S.W., Kim J.H. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 2008, 60:401-407.
38. Yang M., Kang M.J., Choi Y., Kim C.S., Lee S.M., Park C.W., Lee H.S., Tae K. Associations between XPC expression, genotype, and the risk of head and neck cancer. Environ. Mol. Mutagen. 2005, 45:374-379.
39. Yang M., Kim W.H., Choi Y., Lee S.H., Kim K.R., Lee H.S., Tae K. Effects of ERCC1 expression in peripheral blood on the risk of head and neck cancer. Eur. J. Cancer Prev. 2006, 15:269-273.
40. Dabholkar M., Bradshaw L., Parker R.J., Gill I., Bostick-Bruton F., Muggia F.M., Reed E. Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro. Environ. Health Perspect. 1992, 98:53-59.
41. Saviozzi S., Ceppi P., Novello S., Ghio P., Lo Iacono M., Borasio P., Cambieri A., Volante M., Papotti M., Calogero R.A., Scagliotti G.V. Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways. Cancer Res. 2009, 69:3390-3396.
42. Wu Y.H., Tsai Chang J.H., Cheng Y.W., Wu T.C., Chen C.Y., Lee H. Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers. Oncogene 2007, 26:4761-4773.
43. Isla D., Sarries C., Rosell R., Alonso G., Domine M., Taron M., Lopez-Vivanco G., Camps C., Botia M., Nunez L., Sanchez-Ronco M., Sanchez J.J., Lopez-Brea M., Barneto I., Paredes A., Medina B., Artal A., Lianes P. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 2004, 15:1194-1203.
44. Zhou W., Gurubhagavatula S., Liu G., Park S., Neuberg D.S., Wain J.C., Lynch T.J., Su L., Christiani D.C. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 2004, 10:4939-4943.
45. Quintela-Fandino M., Hitt R., Medina P.P., Gamarra S., Manso L., Cortes-Funes H., Sanchez-Cespedes M. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J. Clin. Oncol. 2006, 24:4333-4339.
46. Yoo D.G., Song Y.J., Cho E.J., Lee S.K., Park J.B., Yu J.H., Lim S.P., Kim J.M., Jeon B.H. Alteration of APE1/ref-1 expression in non-small cell lung cancer: the implications of impaired extracellular superoxide dismutase and catalase antioxidant systems. Lung Cancer 2008, 60:277-284.
47. Al-Attar A., Gossage L., Fareed K.R., Shehata M., Mohammed M., Zaitoun A.M., Soomro I., Lobo D.N., Abbotts R., Chan S., Madhusudan S. Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. Br. J. Cancer 2010, 102:704-709.
48. Yang J., Yang D., Cogdell D., Du X., Li H., Pang Y., Sun Y., Hu L., Sun B., Trent J., Chen K., Zhang W. APEX1 gene amplification and its protein overexpression in osteosarcoma: correlation with recurrence, metastasis, and survival. Technol. Cancer Res. Treat. 2010, 9:161-169.
49. Wang D., Xiang D.B., Yang X.Q., Chen L.S., Li M.X., Zhong Z.Y., Zhang Y.S. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer 2009, 66:298-304.
50. Zhang Y., Wang J., Xiang D., Wang D., Xin X. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor. Int. J. Oncol. 2009, 35:1069-1079.
51. Yang S., Irani K., Heffron S.E., Jurnak F., Meyskens F.L. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol. Cancer Ther. 2005, 4:1923-1935.
52. Tell G., Quadrifoglio F., Tiribelli C., Kelley M.R. The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid. Redox Signal. 2009, 11:601-620.
53. Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., Vinolas N., Paz-Ares L., Lopez-Vivanco G., Munoz M.A., Felip E., Alberola V., Camps C., Domine M., Sanchez J.J., Sanchez-Ronco M., Danenberg K., Taron M., Gandara D., Rosell R. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J. Clin. Oncol. 2007, 25:2747-2754.